The CBD-Intel Cosmetics hub provides access to all of our news briefings and regulatory reports about CBD cosmetics, including topicals, balms and related products.
From the EU’s latest rulings to the state-by-state status of CBD cosmetics in the US, keep up to date with the ever-changing international regulatory landscape from this page.
Trends such as sustainability and organic plant-based ingredients are helping to drive the market for hemp and cannabinoid topical products even higher, with combination products all the rage
Suggestions that a Chinese ban on the use of CBD in cosmetics that would essentially shut down the domestic CBD market, blocking imports and cross-border online sales, appear to be premature
Cosmetics have been a mainstay in the CBD market in the US, and there are no signs that is likely to change any time soon. This report offers an overview of the current status of CBD in cosmetics in each US state
The National Advertising Division (NAD) of the US Better Business Bureau has referred advertising claims made by a CBD company to the Federal Trade Commission (FTC)
This short regulatory report provides an overview of the current GMP regulations for cosmetics being place on the market in the EU
Despite a lack of strong evidence for the effectiveness of cannabinoids in dealing with skin issues, more and more UK brands have launched “cannabeauty” ranges, which incorporate skin care, body care and cosmetics
Market limitations in Europe due to EU novel food regulations mean members of the CBD industry are likely to look at areas such as cosmetics and products for animals, according to a number of experts in the field
The regulatory landscape for CBD products varies across the world and constantly changing, making compliance a potential minefield. This report provides an overview of the current legal status of CBD cosmetics in key markets around the world
The launch of many CBD-containing foods, beverages and cosmetics in California has been delayed further as a bill legalising their sale is now not expected to pass before the end of the legislative session, which ends on on 13th September
CBD’s entry in the European Commission’s database of cosmetics ingredients has been expanded to differentiate it from generic cannabis and by-products. The move offers more, but not total, clarity
According to EU authorities, CBD and other cannabis extracts could be deemed illegal as an ingredient in cosmetics. However, individual member states have not made the same interpretation of the rules
In early 2021 the European Commission (EC) made a preliminary decision that extracts from any part of the cannabis plant can be used in cosmetic products, which was big news for the CBD industry. This development should open up the cosmetics market to further innovation because it takes away the requirement that any CBD used must be from synthetic sources in order to avoid legal grey areas in the EU.
If the conclusion is confirmed later in 2021 and the CosIng database is subsequently modified, there could be a flurry of activity in this area as companies with plant extract supply lines look to see what they can do in the growing topicals and cosmetics field. Our news stories will keep you informed of developments in this area.
This preliminary conclusion was agreed internally following discussion and progress on the matter is ongoing. Further information and guidance may be provided in the future with potential changes to CosIng – the European database of cosmetic ingredients – only taking place when the discussions are concluded and a concrete decision has been taken, the Commission added.
Watch this space for our regulatory briefings on developments in the EU and elsewhere in the world that impact the CBD cosmetics industry.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
